{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:53:47Z","timestamp":1789422827894,"version":"build-2803163510"},"reference-count":74,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Menin inhibitors are the first targeted therapies for KMT2A-rearranged and NPM1-mutated acute leukemias, addressing a significant unmet need in these high-risk subtypes. Revumenib received approval in 2024\u20132025 for relapsed or refractory KMT2A-rearranged acute leukemia and NPM1-mutated AML. The AUG-MENT-101 trial reported a 23% composite complete remission rate in heavily pretreated patients, with 61% of responders achieving MRD negativity. Several menin inhibitors, including ziftomenib, bleximenib, and enzomenib, are in clinical development. They demonstrate similar efficacy, but their safety profiles differ, especially regarding QTc prolongation and coverage of resistance mutations. Combination therapies with azacitidine and venetoclax or intensive chemotherapy have achieved high response rates in newly diagnosed patients, supporting their potential use in frontline treatment. Acquired resistance, often due to MEN1 mutations at the drug-binding interface, occurs in about 40% of cases. Distinct resistance patterns among menin inhibitors suggest the possibility of sequential therapy. Approximately 30\u201340% of responders in relapsed or refractory trials proceeded to allogeneic transplantation, which remains a key pathway to potential cure. This review examines the molecular mechanisms of the menin-KMT2A interaction, and summarizes clinical trial data on the efficacy and safety of menin inhibitors as monotherapy and in combination.<\/jats:p>","DOI":"10.3390\/cancers18040637","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:09:54Z","timestamp":1771250994000},"page":"637","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care"],"prefix":"10.3390","volume":"18","author":[{"given":"Caterina","family":"Alati","sequence":"first","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-4406","authenticated-orcid":false,"given":"Matteo","family":"Molica","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Azienda Universitaria Ospedaliera Renato Dulbecco, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-4141","authenticated-orcid":false,"given":"Martina","family":"Pitea","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Marafioti","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-349X","authenticated-orcid":false,"given":"Gaetana","family":"Porto","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Policastro","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2684-9269","authenticated-orcid":false,"given":"Erica","family":"Bilardi","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Utano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Sgarlata","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1597-1913","authenticated-orcid":false,"given":"Ilaria Maria","family":"Delfino","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Idato","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Santoro","sequence":"additional","affiliation":[{"name":"Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Bio Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7258-475X","authenticated-orcid":false,"given":"Marco","family":"Rossi","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Azienda Universitaria Ospedaliera Renato Dulbecco, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12938-025-01403-7","article-title":"Global, regional, and national burden of acute leukemia and its risk factors from 1990 to 2021 and predictions to 2040: Findings from the global burden of disease study 2021","volume":"24","author":"Han","year":"2025","journal-title":"Biomed. Eng. Online"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Guarnera, L., D\u2019addona, M., Bravo-Perez, C., and Visconte, V. (2024). KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. Int. J. Mol. Sci., 25, Erratum in: Int. J. Mol. Sci. 2024, 25, 11743. https:\/\/doi.org\/10.3390\/ijms252111743. PMID: 39201709; PMCID: PMC11354696.","DOI":"10.3390\/ijms252111743"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2010-08-299990","article-title":"Acute myeloid leukemia with mutated nucleophosmin (NPM1): Is it a distinct entity?","volume":"117","author":"Falini","year":"2011","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","article-title":"Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML","volume":"7","author":"Issa","year":"2023","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-025-01293-x","article-title":"Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: A multicenter study of TROPHY group","volume":"15","author":"Zhang","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1182\/bloodadvances.2021004580","article-title":"Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: The MD Anderson experience","volume":"5","author":"Kantarjian","year":"2021","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1128\/MCB.21.1.224-234.2001","article-title":"Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia","volume":"21","author":"Thorsteinsdottir","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40487-024-00262-x","article-title":"Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation","volume":"12","author":"Thomas","year":"2024","journal-title":"Oncol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cantilena, S., AlAmeri, M., Che, N., Williams, O., and de Boer, J. (2024). Synergistic Strategies for KMT2A-Rearranged Leukemias: Beyond Menin Inhibitor. Cancers, 16.","DOI":"10.3390\/cancers16234017"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104783","DOI":"10.1016\/j.critrevonc.2025.104783","article-title":"Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacy","volume":"213","author":"Dali","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"107924","DOI":"10.1016\/j.leukres.2025.107924","article-title":"Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapies","volume":"157","author":"Yang","year":"2025","journal-title":"Leuk. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"ref_19","unstructured":"(2024, November 15). FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia with a KMT2A Translocation, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation."},{"key":"ref_20","unstructured":"GlobeNewswire (2025, October 27). Syndax Announces FDA Approval of Revuforj\u00ae (Revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia. Available online: https:\/\/ir.syndax.com\/news-releases\/news-release-details\/syndax-announces-fda-approval-revuforjr-revumenib-adult-and."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.str.2015.07.018","article-title":"Evolving Catalytic Properties of the MLL Family SET Domain","volume":"23","author":"Zhang","year":"2015","journal-title":"Structure"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"szae089","DOI":"10.1093\/stcltm\/szae089","article-title":"Targeting chromatin modifying complexes in acute myeloid leukemia","volume":"14","author":"Schurer","year":"2025","journal-title":"Stem Cells Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40364-025-00786-y","article-title":"Insights into KMT2A rearrangements in acute myeloid leukemia: From molecular characteristics to targeted therapies","volume":"13","author":"Zehtabcheh","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1021\/acsmedchemlett.4c00311","article-title":"Design of Potent Menin-KMT2A Interaction Inhibitors with Improved In Vitro ADME Properties and Reduced hERG Affinity","volume":"16","author":"Chapsal","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107777","DOI":"10.1016\/j.jbc.2024.107777","article-title":"Drug-resistant menin variants retain high binding affinity and interactions with MLL1","volume":"300","author":"Ray","year":"2024","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/s41375-024-02368-7","article-title":"Menin inhibitors in pediatric acute leukemia: A comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community","volume":"38","author":"Cuglievan","year":"2024","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dhiman, S., Dhillon, V., and Balasubramanian, S.K. (2024). Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions. Cancers, 16.","DOI":"10.3390\/cancers16223743"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: The AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in Relapsed or Refractory NPM1-Mutated, A.M.L","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv."},{"key":"ref_33","unstructured":"(2025, September 26). FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukemia with a NPM1 Mutation, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 Results: First-in-Human Phase 1\/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2024-198959","article-title":"A First-in-Human Phase 1\/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia","volume":"144","author":"Wu","year":"2024","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2025.08.001","article-title":"Menin inhibition for the treatment of acute leukemia","volume":"62","author":"Wenge","year":"2025","journal-title":"Semin. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/hematology.2025000755","article-title":"The promise of menin inhibitors: From approval to triplet regimens","volume":"2025","author":"Thakur","year":"2025","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-025-01757-4","article-title":"A phase 1\/2 study of DS-1594 menin inhibitor in relapsed\/refractory acute leukemias","volume":"18","author":"Senapati","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: Current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e70326","DOI":"10.1002\/cam4.70326","article-title":"Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia","volume":"13","author":"Yin","year":"2024","journal-title":"Cancer Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Loke, J., Buka, R., and Craddock, C. (2021). Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.659595"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Piccini, M., Pilerci, S., Merlini, M., Grieco, P., Scappini, B., Bencini, S., Peruzzi, B., Caporale, R., Signori, L., and Pancani, F. (2021). Venetoclax-Based Regimens for Relapsed\/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081684"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/ejh.13527","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies","volume":"106","author":"Zucenka","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s40364-023-00547-9","article-title":"Repressing HIF-1\u03b1-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML","volume":"11","author":"Ling","year":"2023","journal-title":"Biomark. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine\/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"ref_51","unstructured":"Wei, A.H., Reyner, J.E., Garciaz, S., Aldoss, I., Pi\u00e9rola, A.A., Allred, A., Dominguez, J.M.A., Barreyro, L., Bories, P., and Daskalakis, N. (2025, January 12\u201315). Rp2d determination of bleximenib in combination with ven+aza: Phase 1b study in ND & R\/R AML with KMT2A\/NPM1 alterations. Proceedings of the European Hematology Association Congress, Milan, Italy."},{"key":"ref_52","unstructured":"Erba, H., Wang, E., Fathi, A., Roboz, G., Madanat, Y., Strickland, S., Balasubramanian, S., Mangan, J., Pratz, K., and Advani, A. (2025, January 12\u201315). Ziftomenib combined with intensive induction chemotherapy (7+3) in newly diagnosed NPM1-M or KMT2A-R acute myeloid leukemia (AML): Updated phase 1a\/b results from Komet-007. Proceedings of the European Hematology Association Congress, Milan, Italy."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1182\/blood-2024-199170","article-title":"Ziftomenib combined with venetoclax\/azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Interim phase 1a results from KOMET-007","volume":"144","author":"Fathi","year":"2024","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1182\/blood-2025-5199","article-title":"Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations","volume":"146","author":"Schuh","year":"2025","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Borlenghi, E., Cattaneo, C., Bertoli, D., Cerqui, E., Archetti, S., Passi, A., Oberti, M., Zollner, T., Giupponi, C., and Pagani, C. (2022). Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Up-A Single Center Experience. Cancers, 14.","DOI":"10.3390\/cancers14194716"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood.2021011917","article-title":"Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1\/FLT3-mutated AML","volume":"138","author":"Carter","year":"2021","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9636897231225821","DOI":"10.1177\/09636897231225821","article-title":"Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia Harboring KMT2A Rearrangement and Its Prognostic Factors","volume":"33","author":"Jiang","year":"2024","journal-title":"Cell Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lacoste, S.A., Gagnon, V., B\u00e9liveau, F., Lavall\u00e9e, S., Collin, V., and H\u00e9bert, J. (2024). Unveiling the Complexity of KMT2A Rearrangements in Acute Myeloid Leukemias with Optical Genome Mapping. Cancers, 16.","DOI":"10.3390\/cancers16244171"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jmoldx.2023.09.006","article-title":"Droplet Digital PCR for Oncogenic KMT2A Fusion Detection","volume":"25","author":"Young","year":"2023","journal-title":"J. Mol. Diagn."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Winters, A.C., and Bernt, K.M. (2017). MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front. Pediatr., 5.","DOI":"10.3389\/fped.2017.00004"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/hem.V20.5.2023510","article-title":"MEN1 Mutations Induce Acquired Resistance to the Menin Inhibitor Revumenib","volume":"20","author":"McMahon","year":"2023","journal-title":"Hematologist"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood-2024-208887","article-title":"Discerning the Landscape of Menin Inhibitor Resistance","volume":"144","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"key":"ref_65","first-page":"1145","article-title":"The menin-KMT2A inhibitor JNJ-75276617 targets leukemia cells harboring MEN1 resistance mutations","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e3503d84","DOI":"10.1097\/01.HS9.0000967412.62331.23","article-title":"Non-Genetic Resistance to Menin Inhibition in AML Is Reversible by Perturbation of KAT6A","volume":"7","author":"Perner","year":"2023","journal-title":"HemaSphere"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-025-01675-5","article-title":"MENIN inhibitor-based therapy in acute leukemia: Latest updates from the 2024 ASH annual meeting","volume":"18","author":"Zheng","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/hematolrep16020024","article-title":"A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia","volume":"16","author":"Candoni","year":"2024","journal-title":"Hematol. Rep."},{"key":"ref_69","first-page":"3439","article-title":"Menin Inhibition with Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"42","author":"Issa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_70","first-page":"1951","article-title":"KMT2A-rearranged acute lymphoblastic leukemia in infants: Current progress and challenges","volume":"110","author":"Stutterheim","year":"2025","journal-title":"Haematologica"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Forghieri, F., Nasillo, V., Paolini, A., Bettelli, F., Pioli, V., Giusti, D., Gilioli, A., Colasante, C., Acquaviva, G., and Riva, G. (2020). NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238975"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Matthews, A.H., Pratz, K.W., and Carroll, M.P. (2022). Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14235906"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.bj.2025.100851","article-title":"Integrating comprehensive genomic profiling in the management of oncology patients: Applications and challenges in Taiwan","volume":"48","author":"Huang","year":"2025","journal-title":"Biomed. J."},{"key":"ref_74","unstructured":"Syndax Pharmaceuticals (2025, September 26). Syndax\u2019s Revuforj (revumenib) included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of relapsed or refractory NPM1 mutated acute myeloid leukemia. Available online: https:\/\/ir.syndax.com\/news-releases\/news-release-details\/syndaxs-revuforjr-revumenib-included-nccn-clinical-practice."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/637\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:19:29Z","timestamp":1771251569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":74,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18040637"],"URL":"https:\/\/doi.org\/10.3390\/cancers18040637","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}